Chronic Pain News and Research

RSS

Millennium Laboratories announces new clinical quantitative assay and drug screening tests for healthcare

Millennium Laboratories, a leading provider of therapeutic drug monitoring and education to physicians and staff treating chronic pain patients, announced today the company’s development and validation of a clinical quantitative assay for the new drug tapentadol (Nucynta™) by liquid chromatography/tandem mass spectrometry (LC-MS/MS).

12 Nov 2009

U.S. DOD grant to study vigabatrin in combination with opiates to manage pain

Catalyst Pharmaceutical Partners, Inc. today reported that a team of neuroscientists at The Feinstein Institute for Medical Research at North Shore-Long Island Jewish Health System (LIJ) has received a $1.2 million grant from the U.S. Department of Defense (DOD) to conduct an animal study of the use of vigabatrin in combination with opiates to effectively manage pain while reducing the potential for opiate addiction.

10 Nov 2009

National Pain Summit calls for better pain care in America

Pain medicine physicians from the American Academy of Pain Medicine (AAPM) continued to advance the call for better pain care as they joined with physician leaders from across the country in a closed-door National Pain Summit that took place adjacent to an AMA meeting last week in Houston, Texas.

10 Nov 2009

Cannabinoid medicine: Challenges for health care providers and its potential benefits for patients

Groundbreaking articles in current issues of Journal of Opioid Management, for the first time explore, in depth, the emergence of cannabinoid medicine, its challenges for health care providers and its potential benefits for patients.

10 Nov 2009

Military personnel with back pain unlikely to return to duty after treatment

Military personnel evacuated out of Iraq and Afghanistan because of back pain are unlikely to return to the line of duty regardless of the treatment they receive, according to research led by a Johns Hopkins pain management specialist.

9 Nov 2009

FDA grants marketing approval for Wright Medical Group's CONSERVE Plus Total Hip Resurfacing System

Wright Medical Group, Inc., a global orthopaedic medical device company, announced today that the United States Food and Drug Administration (FDA) has given approval to the Company to market its original CONSERVE® Plus Total Hip Resurfacing System. Now available in the United States, this innovative total surface arthroplasty system provides surgeons and their patients a bone-conserving alternative to traditional total hip replacement.

9 Nov 2009

Progenics Pharmaceuticals reports financial results for the third quarter of 2009

Progenics Pharmaceuticals, Inc. today announced its results of operations for the third quarter and nine months ended September 30, 2009.

9 Nov 2009

Raptor Pharmaceutical to present oral AMPA-kainate antagonist data at the neuropathic pain conference

Raptor Pharmaceutical Corp., today announced that data from a clinical trial of NGX426, the Company's orally administered non-opioid, AMPA/kainate antagonist, will be presented at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, to be held November 20-21, 2009 in San Francisco.

5 Nov 2009

Spinal Modulation completes its $27.4 million Series C financing

Spinal Modulation, Inc. announced today the completion of its $27.4 million Series C financing. Johnson & Johnson Development Corporation (JJDC) joined existing major investors including DeNovo Ventures, ePlanet/DFJ, Kleiner Perkins Caufield & Byers, and MedVenture Associates in this financing. DFJ/InCube Ventures and Raffles Venture Partners are additional new investors.

4 Nov 2009

Researchers to find better ways to manage chronic pain by treating neuroinflammation

Thanks to a two year, $974,024 NIH-funded ARRA (American Recovery and Reinvestment Act) grant, Saint Louis University and Southern Illinois University Edwardsville researchers are working to find better ways to manage chronic pain by treating neuroinflammation.

4 Nov 2009

Obese lung cancer patients with diabeties more likely to develop chest wall pain after receiving stereotactic body radiation therapy

Obesity, not the amount of radiation given, is the greatest factor in whether early-stage lung cancer patients develop chest wall pain after receiving stereotactic body radiation therapy to the chest wall, with obese patients being more than twice as likely to develop chronic pain compared to those who have less body weight, according to a first-of-its-kind study presented Tuesday, November 3, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO).

4 Nov 2009

NIH awards $2 million grant for sickle cell disease research

Researchers at the University of Illinois at Chicago will use a $2 million federal grant to investigate why patients with sickle cell disease experience chronic pain -- and to develop drugs to treat it.

2 Nov 2009

New hope for chronic pain sufferers

In an Anglo-Italian study, thirty healthy subjects were invited to look at either their own hand, the experimenter's hand, or an object, while their hand was subjected to laser-induced pain.

30 Oct 2009

Highlights of new cancer research to be presented at 51st ASTRO Annual Meeting

The following are highlights of new cancer research being presented at the American Society for Radiation Oncology's (ASTRO) 51st Annual Meeting on November 1-5, 2009, in Chicago.

29 Oct 2009

Discovery of AVM can relieve pain due to chronic back pain and neurologic deficits

The discovery of a multi-level arteriovenous malformation (AVM) in the thoracic epidural space can now bring relief to potentially thousands of suffers of chronic thoracic pain and progressive myelopothy. Identified as thoracic epidural arteriovenous malformation (T.E.A.M.), this particular AMV primarily affects younger women ages 20 to 40.

27 Oct 2009

Alkermes commences ALKS 37 phase 1 clinical trial for the treatment of opioid-induced constipation

Alkermes, Inc. today announced the initiation of a phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the opioid agonist effects on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled study will assess the safety, tolerability and pharmacokinetic effects of a single oral administration of five doses of ALKS 37 in approximately 40 healthy volunteers.

27 Oct 2009

Lack of optimal pain care delivery system costs more than $100 billion each year

A new Pain Medicine Position Paper published by leaders of the American Academy of Pain Medicine (AAPM), reveals businesses lose $61 billion annually due to ineffective pain care and the lack of optimal pain care delivery.

27 Oct 2009

Analysis from Phase 3 trials of HZT-501 presented at 74th ACG meeting

Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today presented an analysis from two pivotal Phase 3 trials (REDUCE-1 and REDUCE-2) evaluating its lead investigational compound HZT-501, a combination of ibuprofen with high-dose famotidine.

26 Oct 2009

San Francisco Business Times ranks VitalWear as one of the fastest-growing private companies in the Bay Area

VitalWear, Inc. (www.vitalwear.com), a leader in thermal therapy medical devices announced that the San Francisco Business Times honored the company as one of the fastest-growing private companies in the Bay Area for 2009. VitalWear was ranked #17 out of 100 companies.

26 Oct 2009

Neuros Medical announces $1.8 million series A round of investment

Neuros Medical, Inc., a medical device company developing innovative neurostimulation technology for the treatment of chronic pain, announced today a $1.8 million series A round of investment, led by the North Coast Angel Fund (NCAF), which was joined in the investment by Glengary LLC, Ohio Tech Angel Fund, Queen City Angels First Fund III, and individual investors. This round follows the initial investment made earlier in the year from JumpStart Ventures and Case Technology Ventures.

24 Oct 2009

Chronic Pain News and Research

Millennium Laboratories announces new clinical quantitative assay and drug screening tests for healthcare

U.S. DOD grant to study vigabatrin in combination with opiates to manage pain

National Pain Summit calls for better pain care in America

Cannabinoid medicine: Challenges for health care providers and its potential benefits for patients

Military personnel with back pain unlikely to return to duty after treatment

FDA grants marketing approval for Wright Medical Group's CONSERVE Plus Total Hip Resurfacing System

Progenics Pharmaceuticals reports financial results for the third quarter of 2009

Raptor Pharmaceutical to present oral AMPA-kainate antagonist data at the neuropathic pain conference

Spinal Modulation completes its $27.4 million Series C financing

Researchers to find better ways to manage chronic pain by treating neuroinflammation

Obese lung cancer patients with diabeties more likely to develop chest wall pain after receiving stereotactic body radiation therapy

NIH awards $2 million grant for sickle cell disease research

New hope for chronic pain sufferers

Highlights of new cancer research to be presented at 51st ASTRO Annual Meeting

Discovery of AVM can relieve pain due to chronic back pain and neurologic deficits

Alkermes commences ALKS 37 phase 1 clinical trial for the treatment of opioid-induced constipation

Lack of optimal pain care delivery system costs more than $100 billion each year

Analysis from Phase 3 trials of HZT-501 presented at 74th ACG meeting

San Francisco Business Times ranks VitalWear as one of the fastest-growing private companies in the Bay Area

Neuros Medical announces $1.8 million series A round of investment

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News